{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:23:57Z","timestamp":1794025437058,"version":"4.8.0"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,11,1]]},"DOI":"10.2169\/internalmedicine.6846-25","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:09:36Z","timestamp":1773094176000},"page":"2864-2867","source":"Crossref","is-referenced-by-count":1,"title":["<i>Helicobacter pylori<\/i> Eradication Therapy-induced Severe Hypoglycemia in a Hemodialysis Patient with Type 2 Diabetes Mellitus"],"prefix":"10.2169","volume":"65","author":[{"given":"Miyo","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Diabetology and Endocrinology, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Diabetology and Endocrinology, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Diabetology and Endocrinology, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Diabetology and Endocrinology, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Diabetology and Endocrinology, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Diabetology and Endocrinology, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Hida","sequence":"additional","affiliation":[{"name":"Department of Diabetology and Endocrinology, NHO Okayama Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Khamaisi M, Leitersdorf E. Severe hypoglycemia from clarithromycin-repaglinide drug interaction. Pharmacotherapy 28: 682-684, 2008.","DOI":"10.1592\/phco.28.5.682"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Bussing R, Gende A. Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction. Diabetes Care 25: 1659-1660, 2002.","DOI":"10.2337\/diacare.25.9.1659-a"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Parekh TM, Raji M, Lin YL, et al. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. JAMA Intern Med 174: 1605-1612, 2014.","DOI":"10.1001\/jamainternmed.2014.3293"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Schelleman H, Bilker WB, Brensinger CM, et al. Anti-infectives and risk of severe hypoglycemia in glipizide and glyburide users. Clin Pharmacol Ther 88: 214-222, 2010.","DOI":"10.1038\/clpt.2010.74"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kennedy KE, Teng C, Patek TM, et al. Hypoglycemia associated with antibiotics alone and in combination with sulfonylureas and meglitinides: an epidemiologic surveillance study of the FDA Adverse Event Reporting System (FAERS). Drug Saf 43: 363-369, 2020.","DOI":"10.1007\/s40264-019-00901-7"},{"key":"6","unstructured":"6. Wakuta K, Maekawa Y, Watanabe K, et al. Hypoglycemia caused by the concurrent administration of oral antidiabetic agents for type 2 diabetes and vonoprazan for Helicobacter pylori eradication: a case report. Tonyobyo (J Japan Diab Soc) 63: 339-343, 2020 (in Japanese)."},{"key":"7","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1186\/s12889-023-16689-2","volume":"23","author":"A Chang","year":"2023","unstructured":"7. Chang A, Chang A, Chen WT, Chan L, Hong CT, Chien LN. Triple therapy for Helicobacter pylori eradication and the risk of hypoglycemia in patients with diabetes: a population-based cohort study. BMC Public Health 23: 1772, 2023.","journal-title":"BMC Public Health","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2458","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Pakkir Maideen NM, Manavalan G, Balasubramanian K. Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATPs. Ther Adv Endocrinol Meta 9: 259-268, 2018.","DOI":"10.1177\/2042018818767220"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sakurai Y, Shiino M, Okamoto H, et al. Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study. Adv Ther 33: 1519-1535, 2016.","DOI":"10.1007\/s12325-016-0374-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lee WY, Oh E, Cui M, Kim CO, et al. Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects. Transl Clin Pharmacol 28: 55-65, 2020.","DOI":"10.12793\/tcp.2020.28.e5"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 4: 1121-1127, 2009.","DOI":"10.2215\/CJN.00800209"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Niemi M, Neuvonen PJ, Kivist\u00f6 KT. The cytochrome P450 3A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 70: 58-65, 2001.","DOI":"10.1067\/mcp.2001.116511"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Mainz D, Borner K, Koeppe P, et al. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. J Antimicrob Chemother 50: 699-706, 2002.","DOI":"10.1093\/jac\/dkf172"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-245, 1981.","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/21\/65_6846-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:32:57Z","timestamp":1794022377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/21\/65_6846-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":14,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6846-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11,1]]},"article-number":"6846-25"}}